{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:37:50Z","timestamp":1787769470407,"version":"build-2784847793"},"reference-count":56,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007210","name":"Varian Medical Systems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007210","name":"Varian Medical Systems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Intercept and Genfit"},{"DOI":"10.13039\/100007210","name":"Varian Medical Systems Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.clon.2020.01.028","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T07:56:10Z","timestamp":1582271770000},"page":"423-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Stereotactic Body Radiotherapy for Large Unresectable Hepatocellular Carcinomas \u2013 A Single Institution Phase II Study"],"prefix":"10.1016","volume":"32","author":[{"given":"L.","family":"Beaton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Rackley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Yong-Hing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"DeVries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Duzenli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Loewen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Schellenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2020.01.028_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clon.2020.01.028_bib2","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.clon.2020.01.028_bib3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clon.2020.01.028_bib4","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1445-2197.2012.06079.x","article-title":"Surgical treatment for large hepatocellular carcinoma: does size matter?","volume":"82","author":"Tsoulfas","year":"2012","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.clon.2020.01.028_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/archsurg.140.5.450","article-title":"Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma","volume":"140","author":"Pawlik","year":"2005","journal-title":"Arch Surg"},{"key":"10.1016\/j.clon.2020.01.028_bib6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.clon.2020.01.028_bib7","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2020.01.028_bib8","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.clon.2020.01.028_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1148\/radiol.2241011262","article-title":"Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials","volume":"224","author":"Camma","year":"2002","journal-title":"Radiology"},{"key":"10.1016\/j.clon.2020.01.028_bib10","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/hepr.12083","article-title":"Recurrences of hepatocellular carcinoma following complete remission by transarterial chemoembolization or radiofrequency therapy: focused on the recurrence patterns","volume":"43","author":"Park","year":"2013","journal-title":"Hepatol Res"},{"key":"10.1016\/j.clon.2020.01.028_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jvir.2012.12.013","article-title":"Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension?","volume":"24","author":"Golfieri","year":"2013","journal-title":"J\u00a0Vasc Intervent Radiol"},{"key":"10.1016\/j.clon.2020.01.028_bib12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2020.01.028_bib13","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib15","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2020.01.028_bib16","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib17","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3109\/0284186X.2013.820342","article-title":"Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients","volume":"53","author":"Sanuki","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s12094-010-0492-x","article-title":"Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma","volume":"12","author":"Cardenes","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.radonc.2015.04.006","article-title":"Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma","volume":"115","author":"Huertas","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/jrr\/rru130","article-title":"Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma","volume":"56","author":"Yamashita","year":"2015","journal-title":"J\u00a0Radiat Res"},{"key":"10.1016\/j.clon.2020.01.028_bib22","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2007.14.3529","article-title":"Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"26","author":"Tse","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib23","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/j.ijrobp.2011.04.011","article-title":"Stereotactic body radiotherapy for primary hepatocellular carcinoma","volume":"81","author":"Andolino","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2020.01.028_bib24","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00432-015-1929-y","article-title":"The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT)","volume":"141","author":"Scorsetti","year":"2015","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.2015.61.4925","article-title":"Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma","volume":"34","author":"Wahl","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib26","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1200\/JCO.2002.07.093","article-title":"Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy \u2013 hepatobiliary questionnaire","volume":"20","author":"Heffernan","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0895-4356(96)00428-3","article-title":"Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement","volume":"50","author":"Groenvold","year":"1997","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clon.2020.01.028_bib28","series-title":"EORTC QLQ-C30 scoring manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.clon.2020.01.028_bib29","unstructured":"FACT-HEP Questionairre. Version 4. Available at https:\/\/www.facit.org\/FACITOrg\/Questionnaires"},{"key":"10.1016\/j.clon.2020.01.028_bib30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.clon.2019.01.012","article-title":"Stereotactic body radiotherapy for small unresectable hepatocellular carcinomas","volume":"31","author":"Yeung","year":"2019","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib31","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.clon.2020.01.028_bib32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.clon.2020.01.028_bib33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib34","first-page":"1753","article-title":"Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials","volume":"19","author":"Maringwa","year":"2011","journal-title":"Supp Care Cancer"},{"key":"10.1016\/j.clon.2020.01.028_bib35","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/annonc\/mdj072","article-title":"Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma","volume":"17","author":"Steel","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.radonc.2018.01.004","article-title":"A\u00a0prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy","volume":"126","author":"Moon","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.radonc.2016.07.020","article-title":"Stereotactic body radiotherapy for primary hepatic malignancies - Report of a phase I\/II institutional study","volume":"121","author":"Weiner","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib38","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","article-title":"Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma","volume":"31","author":"Bujold","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib39","doi-asserted-by":"crossref","first-page":"e9249","DOI":"10.1097\/MD.0000000000009249","article-title":"Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma","volume":"96","author":"Kuo","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.clon.2020.01.028_bib40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13014-017-0851-7","article-title":"Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma","volume":"12","author":"Gkika","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib41","first-page":"177","article-title":"Liver dosimetric evaluation in biologically based stereotactic body radiotherapy for large inoperable hepatocellular carcinoma","volume":"4","author":"Loewen","year":"2015","journal-title":"J\u00a0Radiat Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib42","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ijrobp.2009.09.009","article-title":"Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication","volume":"78","author":"Son","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2020.01.028_bib43","series-title":"Stereotactic ablative body radiation therapy (SABR): a resource","author":"Consortium","year":"2019"},{"key":"10.1016\/j.clon.2020.01.028_bib44","unstructured":"Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00672178."},{"key":"10.1016\/j.clon.2020.01.028_bib45","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/cncr.29878","article-title":"Solutions that enable ablative radiotherapy for large liver tumors: fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance","volume":"122","author":"Crane","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2020.01.028_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818790217","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma: current trends and controversies","volume":"17","author":"Schaub","year":"2018","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.clon.2020.01.028_bib47","article-title":"Radiation dose-volume effects for liver SBRT","author":"Miften","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2020.01.028_bib48","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaoncol.2015.2189","article-title":"Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"1","author":"Huo","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib49","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/lt.23439","article-title":"Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation","volume":"18","author":"O'Connor","year":"2012","journal-title":"Liver Transplant"},{"key":"10.1016\/j.clon.2020.01.028_bib50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13014-017-0899-4","article-title":"Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable hepatocellular carcinoma","volume":"12","author":"Moore","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib51","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/jso.22104","article-title":"Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response","volume":"105","author":"Facciuto","year":"2012","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.clon.2020.01.028_bib52","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","article-title":"Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis","volume":"67","author":"Sapisochin","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clon.2020.01.028_bib53","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/hepr.12874","article-title":"Clinical results of proton beam therapy for hepatocellular carcinoma over 5 cm","volume":"47","author":"Kimura","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.clon.2020.01.028_bib54","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ijrobp.2009.02.030","article-title":"Proton beam therapy for large hepatocellular carcinoma","volume":"76","author":"Sugahara","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2020.01.028_bib55","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.24451","article-title":"Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic Liver Cancer stages: a European evaluation","volume":"54","author":"Sangro","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.clon.2020.01.028_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133488","article-title":"Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis","volume":"10","author":"Vincenzi","year":"2015","journal-title":"PLoS One"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655520300364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655520300364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:47:29Z","timestamp":1760543249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655520300364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0936655520300364"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2020.01.028","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Body Radiotherapy for Large Unresectable Hepatocellular Carcinomas \u2013 A Single Institution Phase II Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2020.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}